Physician profile
Alexander E Kalenak
NPI 1831123496
$2,475.41
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $208 · 2021: $297 · 2022: $987 · 2023: $696 · 2024: $47.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.28 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.94 | 2021-2024 | |
| Novo Nordisk INC | $294.33 | 2019-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $235.45 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $197.72 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $141.43 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $112.11 | 2019-2023 | M-M-R II, Gardasil 9, Vaxelis |
| Abbott Laboratories | $102.41 | 2022-2023 | Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $101.62 | 2019-2023 | Breztri, Farxiga |
| Amgen INC. | $83.36 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.47 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $67.63 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.51 | 2022 | |
| Dexcom, INC. | $50.62 | 2022-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $41.35 | 2022 | |
| Astellas Pharma US INC | $37.22 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.94 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.82 | 2019-2021 | |
| Sanofi Pasteur INC. | $30.34 | 2019-2023 | |
| Amarin Pharma, INC. | $26.90 | 2020 | |
| Exact Sciences Corporation | $23.92 | 2023 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $19.08 | 2021 | |
| Redhill Biopharma INC. | $18.35 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.22 | 2023 | |
| Mylan Specialty L.P. | $15.71 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.61 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.59 | 2021 | |
| Boston Scientific Corporation | $13.07 | 2022 | |
| Medtronic Minimed, INC. | $12.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.18 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.17 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Kalenak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.